To keep blood sugar under control and a single therapy is no longer enough. Aifa, the Italian drug agency, has just approved the combination of a latest generation active ingredient, dulaglutide, with oral hypoglycemic Sglt-2 inhibitors, when these are no longer effective enough. The new indication comes from the evaluation of the data of an international study that showed that dulaglutide allows to improve glycemic control compared to Sglt-2 inhibitors alone. This therapy involves only one injection per week and protects against the possibility of hypo and hyperglycemia, also helping to reduce weight and decreasing the risk of cardiovascular events even in those who do not have an established cardiovascular disease.
“Type 2 diabetes progresses over time, so often patients are gradually forced to change their lifestyle and therapies to maintain the same glycemic goals – observes Angelo Avogaro, director of the complex Metabolism Diseases Unit. of the University of Padua hospital company and elected president of the Italian Diabetes Society – The approval by Aifa of the association of dulaglutide with Sglt-2 inhibitors is a great help “.
The study data showed that the two drugs together improve metabolic control as early as six months. Furthermore, dulaglutide allows for a significant decrease in body weight and is the only drug for which a cardiovascular event risk reduction effect has been shown even in patients without established cardiovascular disease. The weight reduction and glycemic control possible with dulaglutide are dose-dependent, meaning they increase with increasing drug dosage. “The results” of the research work “show that higher doses allow for improved glycemic control and also significantly increasing weight loss – explains Enzo Bonora, director of the complex operating unit of endocrinology, diabetology and metabolic diseases of the ” Integrated University Hospital of Verona – With the standard dosage of 1.5 milligrams the glycated hemoglobin drops by 1.5% and about 3 kg are lost, with dulaglutide 3 milligrams the glycate is lowered by 1.7% and the weight decreases by about 4 kg, with the maximum dosage the glycated hemoglobin decreases by 1.9% and almost 5 kg are lost on average, very relevant data in absolute terms; all this without affecting tolerability “.
breaking latest news © Copyright ANSA
.